KIORA PHARMACEUTICALS INC

Developing advanced small molecule therapies for vision-threatening retinal diseases.

KPRX | US

Overview

Corporate Details

ISIN(s):: US49721T3095
LEI:
Country:: United States of America
Address:: 169 SAXONY RD., 92024 ENCINITAS
Website:: https://kiorapharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kiora Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing advanced therapies for retinal diseases. The company utilizes innovative small molecules to target critical biological pathways that underlie vision-threatening conditions. Kiora's development pipeline concentrates on ophthalmic diseases with limited or no effective treatments, aiming to slow, stop, or restore vision loss for patients with these unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all KIORA PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KIORA PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for KIORA PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA
Intercure Ltd. Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.	Israel	INCR
Intercure Ltd. A leading producer of pharmaceutical-grade, GMP-certified medical cannabis products.	United States of America	INCR
Intervacc AB Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.	Sweden	IVACC
iNtRON Biotechnology, Inc. Develops phage therapeutics and molecular diagnostics to combat infectious diseases.	South Korea	048530
Inventage Lab Inc. Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.	South Korea	389470
Inventiva S.A. Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.	United States of America	IVA
Invivyd, Inc. Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.	United States of America	IVVD
IO Biotech, Inc. Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.	United States of America	IOBT
IONIS PHARMACEUTICALS INC A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.	United States of America	IONS